More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 31, 2024 Adaptive.
Adaptive Biotechnologies Announces Data Supporting the globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Binod Dhakal, MD, associate professor, Medical College of Wisconsin, is lead investigator of the CARTITUDE-4 study, drom which data were used by the FDA to approve ciltacabtagene autoleucel (cilta-cel) for patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 1 prior line of therapy.
Sagar Lonial, MD, FACP, details additional agents of interest outside CAR T-cell therapies in multiple myeloma including the recently approved agents elranatamab and talquetamab.